The Epigenomic Landscape of Dilated Cardiomyopathy

s S161 such limitations. An added benefit of such partnership is to increase access to NIH-IRP state-of-the-art basic and clinic research infrastructure and diversity research opportunities. In keeping with this recommendation, the National Heart, Lung and Blood Institute (NHLBI) recently created GRAfT (Genomic Research Alliance for Organ Transplantation), an intramural-extramural alliance to study acute and chronic rejection and fast-track development noninvasive diagnostic tools in thoracic organ transplantation. Methods: GRAfT has engaged 7 thoracic transplant programs in the Washington DC area averaging 180 thoracic transplants yearly, with about 1,345 active transplant recipients, of which 32.4% are non-Caucasians and 37.8% are women. Through NHLBI’s Laboratory of Transplant Genomics, GRAfT is developing high throughput genomic tools measuring cell-free DNA. These tools have been shown to have good performance in assessing graft injury, immunosuppression, and infections. So far, 30 patients have been enrolled in GRAfT with goal to enroll 500 patients and a mean follow-up of 5 years. Clinical data and biospecimen will be collected and achieved at LoTG. A steering committee comprising intramural and extramural investigators sets the research agenda and manages the biorepository. Working groups will address specific research questions. Biorepository will be accessible to intramural and extramural investigators. Preliminary results expected in March 2015. Endpoints: Acute rejection, Infection, Chronic rejection, other transplant comorbidities.